Loading...
XPAR
DIM
Market cap21bUSD
Sep 17, Last price  
196.10EUR
1D
1.13%
1Q
20.09%
Jan 2017
227.00%
Name

Sartorius Stedim Biotech SA

Chart & performance

D1W1MN
XPAR:DIM chart
P/E
71.84
P/S
6.43
EPS
2.73
Div yield, %
0.35%
Shrs. gr., 5y
1.09%
Rev. gr., 5y
9.21%
Revenues
2.97b
+6.74%
521,053,000268,836,000367,996,000401,231,000432,949,000477,300,000543,964,000588,378,000683,524,000884,331,0001,051,611,0001,081,033,0001,212,152,0001,440,570,0001,910,081,0002,886,977,0003,492,700,0002,775,500,0002,780,000,0002,967,500,000
Net income
266m
+51.68%
29,019,0004,742,00013,104,00029,092,00038,511,00043,190,00056,756,00066,276,00072,472,000117,999,000153,678,000161,088,000208,052,000234,574,000335,932,000414,400,000876,100,000309,700,000175,100,000265,600,000
CFO
539m
-33.92%
51,715,00026,021,00047,226,00091,855,00072,759,00060,593,00048,927,00090,106,000111,312,000142,789,000156,659,000174,689,000227,289,000310,129,000416,879,000695,971,000612,300,000746,400,000815,100,000538,600,000
Dividend
Mar 31, 20260.69 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.

Related entities

Parent
Subsidiaries
Sartorius Stedim Biotech GmbH

Key people

Bernard Lemaitre
Non-Executive Director · since 2007
Susan Dexter
Non-Executive Independent Director · since 2015
Non-Executive Independent Director · since 2015
Henri Riey
Non-Executive Independent Director · since 2007
IPO date
Oct 20, 1994
Employees
11,135
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
Avenue de Jouques, ZONE INDUSTRIELLE LES PALUDS
Aubagne, PAC 13400
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT